Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 12:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 2,690 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Normal saline solution Clear all

Conditions: Bronchiolitis
Interventions: Nebulized 3% saline, Nebulized 0.9% saline; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: Up to 24 Months
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Los Angeles, California • Oakland, California

Conditions: SARS-CoV-2
Interventions: mRNA-1273, Placebo, mRNA-1273.214; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 6 Months to 11 Years
Enrollment: 11,942 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 83
States / cities: Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 68 more

Conditions: Plasmodium Falciparum Infection
Interventions: Chloroquine, PfSPZ (NF54) Challenge, Placebo; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Lymphoma
Interventions: filgrastim, busulfan, melphalan, thiotepa, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Up to 70 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Heart Failure, Congestive, Cardiomyopathy
Interventions: recombinant B-type, natriuretic peptide, placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
Interventions: anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Up to 60 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan
Interventions: Aminophylline, Placebo; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Blood And Marrow Transplantation
Interventions: Cidofovir, Probenecid; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fever
Interventions: Ibuprofen, Normal Saline; Drug · Other
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 8
States / cities: Orlando, Florida • St Louis, Missouri • Greensboro, North Carolina + 4 more

Conditions: Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions: Abatacept, Normal Saline, D5W; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 6 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 27
States / cities: Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more

Conditions: Perianal Crohn Disease, Perianal Fistula, Crohn Disease
Interventions: Mesenchymal Stem Cells, Placebo; Drug · Other
Lead sponsor: Anthony Lembo; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), Significant Memory Concern (SMC), Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI)
Interventions: Florbetapir, Flortaucipir; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 55 Years to 90 Years
Enrollment: 1,182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 53
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 43 more

Conditions: Pain
Interventions: naloxone, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Post COVID-19 Condition, Long COVID
Interventions: Rintatolimod, Placebo / Normal Saline; Drug · Other
Lead sponsor: AIM ImmunoTech Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 5
States / cities: Canoga Park, California • Inglewood, California • San Diego, California + 2 more

Conditions: Paravertebral Catheter Insertion, Mastectomy, Breast Cancer
Interventions: Placebo (normal saline) Continuous Infusion, Ropivicaine 0.4% Continuous Infusion; Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Pelvic Organ Prolapse
Interventions: Platelet rich plasma (PRP) Injection, Placebo; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Lateral Canthus Rhytides, Crow's Feet Lines
Interventions: onabotulinumtoxinA, normal saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Immunoglobulin A Nephropathy, Glomerular Disease, IgAN
Interventions: Dose-Placebo, Low Dose-VIS649, Medium Dose-VIS649, High Dose-VIS649; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • Oxnard, California + 13 more

Conditions: Acute Limb Ischemia
Interventions: MST-188, Saline; Drug
Lead sponsor: Mast Therapeutics, Inc.; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 4
States / cities: Little Rock, Arkansas • Tampa, Florida • Brooklyn, New York + 1 more

Conditions: Septic Shock
Interventions: Hydrocortisone, sodium succinate, Normal saline; Drug
Lead sponsor: Jerry Zimmerman; Other
Eligibility: 1 Month to 17 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 18
States / cities: Tucson, Arizona • Los Angeles, California • Oakland, California + 15 more

Conditions: End Stage Renal Disease, Chronic Kidney Diseases
Interventions: Berinert, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Invasive Bladder Cancer
Interventions: Cystectomy, Lidocaine, Saline; Procedure · Drug
Lead sponsor: CAMC Health System; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: ESRD
Interventions: anakinra, actos, placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Depression
Interventions: Infliximab, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 25 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Nebulized Hypertonic Saline for Bronchiolitis

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Study With Aminophylline to Attenuate of the Side Effects of Regadenoson

Intravesical Cidofovir for Hemorrhagic Cystitis

Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease

Alzheimer's Disease Neuroimaging Initiative 2

Subjective Analgesic Effects of Naloxone and Virtual Reality

Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

Prevention of Post-Mastectomy Breast Pain Using Ambulatory Continuous Paravertebral Blocks

Platelet Rich Plasma as an Adjunct Therapy at the Time of Transvaginal Native Tissue Prolapse Surgery

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines

Safety and Efficacy Study of VIS649 for IgA Nephropathy

Evaluation of MST-188 in Acute Lower Limb Ischemia

Stress Hydrocortisone In Pediatric Septic Shock

Berinert (C1INH) vs Placebo for DGF/IRI

Intravenous Lidocaine for Cystectomy Procedures

Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2

A Study of Infliximab for Treatment Resistant Major Depression